Table 4 Baroreflex sensitivity and resonance at baseline, on placebo, and on reb-oxy (n = 16).
Baseline | Placebo | Reb-Oxy | p-value | |
|---|---|---|---|---|
BRS ms/mmHg | ||||
αLF supine | 5.3 [3.8–8.6] | 6.0 [4.2–8.8] | 9.3 [7.8–10.8] | 0.02 |
αLF standing | 2.6 [2.0–4.6] | 3.1 [2.0–4.3] | 3.7 [2.5–6.8] | 0.03 |
HLF supine | 3.9 [2.8–6.6] | 5.1 [3.5–6.8] | 8.2 [5.8–10.5] | 0.01 |
HLF standing | 2.0 [1.6–4.0] | 2.2 [1.5–3.3] | 3.1 [1.9–4.8] | 0.07 |
BRSSEQ supine | 6.7 [4.2–7.6] | 7.2 [3.3–9] | 9.3 [8–12.6] | 0.29 |
BRSSEQ standing | 3.9 [2.3–5.3] | 3.4 [3.2–4.5] | 3.9 [2.4–5] | 0.08 |
Baroreflex resonance, mmHg2 | ||||
SBPLF supine | 7.8 [3.9–14.2] | 9.3 [4.7–11.7] | 2.8 [2.1–3.8] | < 0.01 |
SBPLF standing | 14.6 [11.2–20.4] | 17.0 [10.9–21.4] | 5.8 [4.2–9.8] | < 0.01 |
DBPLF supine | 2.7 [1.9–5.3] | 3.5 [1.8–5.8] | 1.3 [1.1–2.0] | < 0.01 |
DBPLF standing | 5.0 [3.8–9.2] | 5.9 [4.1–9.4] | 2.4 [1.7–3.4] | < 0.01 |